ArticleBiomolecules & biomedicine2024

Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy.

Semir Vranic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.